Logo

Hero

30 January - 31 January 2018 | Excel London

Festival of Genomics

Explore the Agenda

Filter by interest area then click on a session title to find out more

Loading
Theatre 1
  1. Theatre 1
  2. Theatre 1
    •An update on the progress of the 100,000 Genomes Project • How the genomic infrastructure is underpinning the development of personalised medicine across the NHS • The importance of mainstreaming ser ...
  3. Theatre 1
    Further information about this talk will be available shortly
  4. Theatre 1
    • The importance of connecting next-generation sequencing data with other biomedical data to inform clinical decision pathways  • Having the right analytical and interpretation tools available at the ...
  5. Theatre 1
    25 years of genetic medicine have resulted in a rich tapestry of irreplaceable knowledge that can inform present and future research and healthcare. It has also led to a haphazard, inconsistent, error ...
  6. Theatre 1
    Please note - Roche's presentation will now be taking place in drug development on day 2 at 13:25 in Theatre 1. 
  7. Theatre 1
    Intro of Sophia genetics by Gerald Martin Presentation by Adam Molyneaux on SOPHiA our high security standards & robustness of Sophia DDM platform  Angela Silmon  NewGene’s presentation of Sophia DDM ...
  8. Theatre 1
    Overview of the project aims and structure • Deliverables of the Pilot Phase • Planning the next large scale phase
  9. Theatre 1
    Proposed HRA/HTA joint public engagement project on data sharing in relation to tissue for research Broad consent/Dynamic consent Learn how this will feed into joint guidance and how they might contri ...
  10. Theatre 1
    Established protocols suggest that human-origin published genome data should be deposited in public repositories for further reuse. Controlled access data protocols are barely serving their purpose an ...
  11. Theatre 1
    The session will review the experience of using QI methodology for implementing the 100,000 Genomes Project in two London Hospitals, especially how to: Identify leaders, needs and motivators Develop a ...
  12. Theatre 1
  13. Theatre 1
    Warfarin is the most commonly prescribed anticoagulant in England 40 fold variability in warfarin dose requirements among patients Discussion from discovery of an association between the polymorphisms ...
Theatre 2
  1. Theatre 2
  2. Theatre 2
    •Overview of the Global Alliance Overview of approaches taken to make genomic and health data interoperable and sharable • Global standards and tools to make data sharing possible • Politics and strat ...
  3. Theatre 2
    Transformation of cost changing healthcare • Bringing healthcare and research together • Understanding the broad future landscape of genomics in healthcare
  4. Theatre 2
    Further information about this talk will be available shortly
  5. Theatre 2
    Current challenges for transferring sequencing data across the internet • Description of the GA4GH data discovery and streaming API • Implementations and interoperability to date
  6. Theatre 2
    We regret to inform you that this session has been cancelled.
  7. Theatre 2
    A lack of standards hinders data sharing and can increase risk of error A shared annotation model aids variant interpretation A bridge is needed between clinical and genomic data management systems
  8. Theatre 2
    The clinical community becomes gradually engaged in the production of patient exomes A shared resource for massive sequencing data analysis is key for this commitment Allelic frequency in the “normal” ...
  9. Theatre 2
    •DNA analysis lets us understand why disease happens • Human Variome Project seeks to share and understand clinical significance • Global Alliance for Genomics and Health and HVP are creating BRCA Exc ...
  10. Theatre 2
    Purpose of graph genomes • Storage of graph genomes • Display of graph genomes • Uses of graph genomes
Theatre 3
  1. Theatre 3
  2. Theatre 3
    The major clinical challenge of tumour heterogeneity, evolution & drug resistance The importance of linking use of existing targeted drugs to the cancer genome of individual patients – including appro ...
  3. Theatre 3
    Genomics is poised to transform therapeutic decision making Standards are needed to ensure quality, efficiency and sustained availability Here Illumina will share their approach to a standardized plat ...
  4. Theatre 3
    •Cancers are distributed unevenly across the body, but the importance of cell intrinsic factors such as stem cell function in determining organ cancer risk is unknown • This talk describes a study in ...
  5. Theatre 3
    •This will be a two part presentation by Dr Rowena Sharpe, CRUK, and Dr Gary Middleton, University of Birmingham CTU • They will jointly present on CRUK's Stratified Medicine Programme which forms the ...
  6. Theatre 3
    The hunt for mutation signatures in large cancer datasets • Understanding what you can, and can't know from your cancer data
  7. Theatre 3
    The challenges of variant detection in ctDNA How innovative chemistry and software combine to overcome these challenges How open-ended fusion detection lead to the discovery of a novel, recurrent fusi ...
  8. Theatre 3
    Progress in developing breakthrough immuno-therapy treatments fuels research to identify informative biomarkers. We are investigating multiple approaches to identify biomarkers that may be useful in c ...
  9. Theatre 3
    • How do we change the way we treat patients based on the underlying biology and genetics of their particular cancers? • Implementation in the clinic: what's required now and in the future? • What's t ...
Theatre 4
  1. Theatre 4
  2. Theatre 4
    An introduction to precision medicine at CRUK • How Stratified Medicine Programme 2 acts as a pre-screening to the National Lung Matrix Trial How patient involvement adds value to our work
  3. Theatre 4
    Hands on activities to explain personalised medicine: • Genetic taste test • Targeted therapy man • Stratified medicine 'hook-a-ducks'
  4. Theatre 4
    To what extent can an ordinary family know about their own personal genomes? What my family learned by sharing our personal genomes on the web  Using open access data to learn more 
  5. Theatre 4
    Addressing misconceptions and fears about genomic data sharing Who owns patient data? Is open data sharing best for all?
  6. Theatre 4
  7. Theatre 4
    Further details about this talk will be announced soon
  8. Theatre 4
    Adopting synthetic biology approaches to improve the design of gene therapies Synthetic promoters for improved gene expression Lessons to be learned in starting a SynBio business
  9. Theatre 4
    Further information about this talk will be available shortly
  10. Theatre 4
    Further information about this talk will be available shortly
  11. Theatre 4
    DNA and RNA are not the only viable genetic materials DNA polymerases are formidable molecular machines Directed evolution can be a powerful tool for synthetic biology
  12. Theatre 4
    Subtracting the hype: what can we actually look forward to from synthetic biology? Building vs. editing: Is CRISPR Synthetic Biology’s most powerful tool? Novel cures: can synthetic biologists beat ev ...
  13. Theatre 4
    Closing remarks from Twist Biosciences 
Theatre 1
  1. Theatre 1
  2. Theatre 1
    Further information about this talk will be available shortly
  3. Theatre 1
  4. Theatre 1
    •Creating a new ecosystem for drug discovery • De-risking new targets • Making un-druggable targets, druggable
  5. Theatre 1
    Learn about the high sensitivity of PacBio long-read sequencing to detect structural variants (variants larger than 50 bp). Evaluate structural variants generated from 10-fold coverage PacBio sequenci ...
  6. Theatre 1
    • New paradigm in advanced NSCLC - mutation testing at each treatment regimen failure • The need to understand both your target indication and have appropriate diagnostic to accelerate development tim ...
  7. Theatre 1
    Overview of the Roche NGS portfolio Single day RNA-Seq library prep Single day target enrichment workflows
  8. Theatre 1
    •Why a precompetitive partnership is important for target selection and validation and bridge the gap from genetics to drug discovery • A description of how Open Targets brings together academic and i ...
  9. Theatre 1
    Achieving value through biomarker practice Mapping molecular signals at the level of drug and disease Combining data to elucidate new taxonomy; the Preciseaids experience
  10. Theatre 1
    •Examples of real working models for innovation in drug development • How and where to challenge inward facing competitive culture • Creating "incubation space" where academic concepts can be verified ...
Theatre 2
  1. Theatre 2
  2. Theatre 2
    • Overview of PGE and introduction to CRISPR/Cas9 technology • Applications in target finding, hit and lead discovery, efficacy and safety models • AstraZeneca's unique approach towards innovation and ...
  3. Theatre 2
    Analysis techniques including NGS, junction PCR and ddPCR Application of these techniques in genome editing Strengths and challenges of the different techiques looking at different types of modificati ...
  4. Theatre 2
    We regret to inform you that this session has been cancelled. 
  5. Theatre 2
    •Manipulation of gene regulatory elements and which are causing an effect on various disease states
  6. Theatre 2
    • Explore machine learning approaches that work best for CRISPR/Cas9 • Classifying on and off-target sequences • Move towards unbiased analysis
  7. Theatre 2
    Tips and tricks for arrayed and pooled screening  with CRISPR and options available for  pooled library and will illustrate the new Sanger arrayed whole genome library. Results with the recently launc ...
  8. Theatre 2
    How can we streamline the process of generating and scaling up translationally relevant models (both in vitro and in vivo) to benefit all aspects of the drug discovery process?
  9. Theatre 2
    • Is the efficiency of this technology enough for modifying an unborn person? Would it be right to correct a diseased gene? • What would justify doing this experiment on an unborn person? What about e ...
Theatre 3
  1. Theatre 3
  2. Theatre 3
    •Appreciate the challenge of separating noise from signal in data sets combining genomics, imaging and EHR for precision medicine • Understand how new computational and statistical approaches can iden ...
  3. Theatre 3
    Can the translational informatics-enabled healthcare vision be applied to drug discovery? • Can it bring together all the current strands of thinking regarding Big Data, Real World Evidence, digital d ...
  4. Theatre 3
    • Bacterial genome assembly • Mammalian genome assembly • Plant genome assembly • Cloud computing
  5. Theatre 3
    Data is a strategic asset – look after it Automation and industrialisation is not optional The sooner you start the sooner you get control
  6. Theatre 3
    **THIS SESSION HAS BEEN CANCELLED**
  7. Theatre 3
    The UK NHS provides large scale, cradle to grave phenotyping of its 65 million population, posing major opportunities and challenges in the proposed new era of data-based and more precise medicine. Th ...
  8. Theatre 3
    Large-scale analyses of genetic variation in humans have revealed many specific insights into human biology and disease. Knowledge of the consequences of these genetic perturbations is a powerful tool ...
  9. Theatre 3
  10. Theatre 3
    •Where can predictive modelling and network analysis have most impact now and in the future? How can machine learning resources be vetted and validated? • Discuss pros and cons of representing complex ...
  11. Theatre 3
    •Openness matters: introduction of open consent and open data access and how it compares to restricted (managed) access • Democratising genome data through Genome Donations • Introduction of UK Person ...
Theatre 4
  1. Theatre 4
  2. Theatre 4
    Insight into changing practices and suggested models for moving forward • New models of genetic/genomic counselling • Relationships with other specialities and role as a genetics resource • Complexiti ...
  3. Theatre 4
    Considerations for the consent process in the age of genomics: • Making choices in the era of genomics • Specific versus broad consent • What do patients want? • What is the role of the health profess ...
  4. Theatre 4
    A framework for interpreting variants • Direct and indirect evidence • Adding value - the MDT • Communicating variants to your patients
  5. Theatre 4
    We regret to inform you that this session has been cancelled. 

Join the community at the largest free-to-attend genomics event